ESMO-MCBS scores are based on peer reviewed clinical trial reports. They are generated using a validated standard methodology and are reviewed by a team of clinicians and statisticians before publication. ESMO-MCBS scores should be interpreted in the context of an evolving treatment landscape, in connection with clinical practice guidelines.
Treatment of adult patients with mCRPC, symptomatic bone metastases and no known visceral metastases, in progression after ≥2 prior lines of systemic therapy for mCRPC (other than LHRH analogues), or ineligible for any available systemic mCRPC treatment ALSYMPCA
Genitourinary Cancers
Prostate cancer
-
ALSYMPCA
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
SCORE
F2a
4
Abiraterone
Prednisone
Prednisone + placebo
Indicated with prednisone or prednisolone for the treatment of mCRPC in adult men whose disease has progressed on or after a docetaxel-based ChT regimenCOU-AA-301
Genitourinary Cancers
Prostate cancer
-
COU-AA-301
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
SCORE
F2a
4
Enzalutamide
-
Placebo
Adult men with mCRPC whose disease has progressed on or after docetaxel therapyAFFIRM
Genitourinary Cancers
Prostate cancer
-
AFFIRM
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
SCORE
F2a
4
Enzalutamide
-
Placebo
Castraction-refractory pre-docetaxel (early termination with crossover)PREVAIL
Genitourinary Cancers
Prostate cancer
-
PREVAIL
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
SCORE
F2b
4
Docetaxel Q3w
Prednisone or prednisolone
Mitoxantrone ± prednisone or prednisolone
In combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancerTAX 327 study
Genitourinary Cancers
Prostate cancer
-
TAX 327 study
3
PRELIMINARY SCORE
OS
ADJUSTMENTS
SCORE
F2a
3
Cabazitaxel
Prednisone or prednisolone
Mitoxantrone ± prednisone or prednisolone
In combination with prednisone or prednisolone is indicated for the treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimenTROPIC
Genitourinary Cancers
Prostate cancer
-
TROPIC
2
PRELIMINARY SCORE
OS
ADJUSTMENTS
SCORE
F2a
2
Nivolumab
-
Everolimus
As monotherapy for the treatment of advanced renal cell carcinoma after prior therapy in adultsCheckMate025
Genitourinary Cancers
Renal cell cancer
-
CheckMate025
5
PRELIMINARY SCORE
OS
ADJUSTMENTS
SCORE
F2a
5
Axitinib
-
Sorafenib
Treatment of adult patients with advanced RCC after failure of prior treatment with sunitinib or cytokineAXIS
Genitourinary Cancers
Renal cell cancer
-
AXIS
3
PRELIMINARY SCORE
PFS
ADJUSTMENTS
SCORE
F2b
3
Pazopanib
-
Sunitinib
First-line treatment of advanced renal-cell carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease COMPARZ
Genitourinary Cancers
Renal cell cancer
-
COMPARZ
4
PRELIMINARY SCORE
NI
ADJUSTMENTS
SCORE
F2c
4
Sunitinib
-
Interferon
Treatment of advanced/metastatic renal cell carcinoma in adults
Genitourinary Cancers
Renal cell cancer
-
-
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
SCORE
F2b
4
Sorafenib
-
Placebo
Patients with advanced RCC who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapyTARGET
Genitourinary Cancers
Renal cell cancer
-
TARGET
3
PRELIMINARY SCORE
OS
ADJUSTMENTS
SCORE
F2a
3
Everolimus
-
Placebo (Crossover allowed)
Patients with advanced RCC, whose disease has progressed on or after treatment with VEGF-targeted therapyRECORD-1
Genitourinary Cancers
Renal cell cancer
-
RECORD-1
3
PRELIMINARY SCORE
PFS
ADJUSTMENTS
SCORE
F2b
3
Pazopanib
-
Placebo (Crossover allowed)
First-line treatment of advanced renal-cell carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced diseaseStudy VEG105192
Genitourinary Cancers
Renal cell cancer
-
Study VEG105192
3
PRELIMINARY SCORE
PFS
ADJUSTMENTS
SCORE
F2b
3
Bevacizumab
Interferon
Interferon + placebo
In combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancerAVOREN
Genitourinary Cancers
Renal cell cancer
-
AVOREN
3
PRELIMINARY SCORE
PFS
ADJUSTMENTS
SCORE
F2b
3
Cabozantinib
-
Everolimus
As monotherapy as the treatment of advanced renal cell carcinoma in adults following prior vascular endothelial growth factor (VEGF) - targeted therapyMETEOR
Genitourinary Cancers
Renal cell cancer
-
METEOR
3
PRELIMINARY SCORE
OS
ADJUSTMENTS
SCORE
F2a
3
Lenvatinib
Everolimus
Everolimus
Treatment of adults with advanced renal cell carcinoma in combination with everolimus following one prior vascular endothelial growth factor (VEGF)-targeted therapy
Genitourinary Cancers
Renal cell cancer
-
-
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
SCORE
F2a
4
Cabozantinib
-
Placebo
As monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenibCELESTIAL
Gastrointestinal Cancers
Hepatobiliary Cancers - Hepatocellular Carcinoma
-
CELESTIAL
3
PRELIMINARY SCORE
OS
ADJUSTMENTS
SCORE
F2a
3
Regorafenib
-
Placebo
As monotherapy for the treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenibRESORCE
Gastrointestinal Cancers
Hepatobiliary Cancers - Hepatocellular Carcinoma
-
RESORCE
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
SCORE
F2a
4
Nivolumab + ipilimumab
-
Sunitinib
First-line treatment of adult patients with intermediate/poor-risk advanced RCC CheckMate 214
Genitourinary Cancers
Renal cell cancer
-
CheckMate 214
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
SCORE
F2a
4
Tivozanib
-
Sorafenib
First-line treatment and for adult patients who are VEGFR and mTOR pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapyTIVO-1
Genitourinary Cancers
Renal cell cancer
-
TIVO-1
1
PRELIMINARY SCORE
PFS
ADJUSTMENTS
SCORE
F2b
1
FLOT (docetaxel, oxaliplatin, 5-FU, folinic acid)
-
5-FU or capecitabine + cisplatin + epirubicin
Peri-operative locally advanced, resectable gastric or gastroesophageal junction adenocarcinomaFLOT4
Gastrointestinal Cancers
Gastric or gastroesophageal junction adenocarcinoma
-
FLOT4
A
PRELIMINARY SCORE
OS
ADJUSTMENTS
SCORE
F1
A
Gemcitabine
Capecitabine
Gemcitabine
Adjuvant therapy following resection for pancreatic cancerESPAC-4
Gastrointestinal Cancers
Pancreatic cancer
-
ESPAC-4
A
PRELIMINARY SCORE
OS
ADJUSTMENTS
SCORE
F1
A
mFOLFIRINOX
-
Gemcitabine
Adjuvant therapy following resection for pancreatic cancerPRODIGE 24/CCTG PA.6
Gastrointestinal Cancers
Pancreatic cancer
-
PRODIGE 24/CCTG PA.6
A
PRELIMINARY SCORE
OS
ADJUSTMENTS
SCORE
F1
A
Nanoliposomal irinotecan
5-FU/LV
5-FU/LV
Treatment of metastatic adenocarcinoma of the pancreas, in combination with 5 fluorouracil (5 FU) and leucovorin (LV), in adult patients who have progressed following gemcitabine-based therapyNAPOLI-1
Gastrointestinal Cancers
Pancreatic cancer
-
NAPOLI-1
3
PRELIMINARY SCORE
OS
ADJUSTMENTS
SCORE
F2a
3
Osimertinib
-
Gefitinib or erlotinib
Previously untreated EGFR mutated (exon 19 deletion or L858R)FLAURA
Thoracic Malignancies
Non-small-cell Lung Cancer
EGFR+ (exon 19 deletion or L858R)
FLAURA
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
SCORE
F2b
4
Alectinib
-
Crizotinib
As monotherapy is indicated for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).ALEX
Thoracic Malignancies
Non-small-cell Lung Cancer
ALK+
ALEX
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
SCORE
F2a
4
Alectinib
-
Chemotherapy (pemetrexed or docetaxel)
As monotherapy is indicated for the treatment of adult patients with ALK‑positive advanced NSCLC previously treated with crizotinibALUR
Thoracic Malignancies
Non-small-cell Lung Cancer
ALK+
ALUR
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
SCORE
F2b
4
Atezolizumab
-
Docetaxel
As monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapyOAK
Thoracic Malignancies
Squamous or non-squamous non-small-cell lung cancer
-
OAK
5
PRELIMINARY SCORE
OS
ADJUSTMENTS
SCORE
F2a
5
Ceritinib
-
Chemotherapy (pemetrexed or docetaxel)
Treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non small cell lung cancer (NSCLC) previously treated with crizotinibASCEND-5
Thoracic Malignancies
Non-small-cell Lung Cancer
ALK+
ASCEND-5
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
SCORE
F2b
4
Ceritinib
-
Chemotherapy
Frist-line treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non small cell lung cancer (NSCLC) stage IIIB/IV ASCEND-4
Thoracic Malignancies
Non-small-cell Lung Cancer
ALK+
ASCEND-4
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
SCORE
F2b
4
Watchlist
Tested Agent(s)
Combined Agent(s)
Control Arm
Therapeutic Indication
Tumour Type
Tumour Sub-type
Tumour Sub-group
Trial Name
Ref.
Score
Scorecard
Scorecard
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.